22EL-766 On-Demand Hot Topic Discussion: Impact of Injectable PrEP on Donor Testing and Screening

Please note: AABB reserves the right to make updates to this program.

Live Program Date: Thursday, August 18, 2022
Program Number: 22EL-766

Faculty
(titles and affiliations at the time of the live program)
Moderator: Sharon Carayiannis, MT(ASCP)HP, Vice President, Science and Practice, Association for the Advancement of Blood & Biotherapies (AABB)
Speakers: Jed B. Gorlin, MD, MBA, Vice President and Medical Director, Innovative Blood Resources; Chair, AABB Transfusion Transmitted Diseases Committee; Brian Custer, PhD, MPH, Director, Vitalant Research Institute; Senior Vice President, Research and Scientific Programs, Vitalant; Adjunct Professor, Department of Laboratory Medicine, University of California San Francisco; Mary Townsend, MD, Senior Medical Director, National Office, Vitalant; Chair, AABB Donor History Task Force

Program Description
This program will provide new information regarding the potential impact of donor use of long-acting, injectable cabotegravir as pre-exposure prophylaxis (PrEP) approved by FDA in late December 2021, and new considerations for donor testing and screening. Expert speakers will provide brief presentations, followed by a question and discussion period.

Program Sponsor
This program is complimentary to AABB individual members through the generous support of Ashland, an AABB Premium Corporate Partner.